High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Chinese patients: A retrospective study of 82 cases

European Journal of Dermatology

Volumn 20, Issue 6, 2010, Pages 743-747

  Chen, Jinbo ^a   Wang, Baoxi ^a   Zeng, Yueping ^a   Xu, Haoxiang ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Retrospective studies; Stevens Johnson Syndrome; Toxic epidermal necrolysis

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIGOUT AGENT; ANTIPODAGRIC AGENT; CARBAMAZEPINE; HYDROCORTISONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; SULFANILAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHINESE; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PROGNOSIS; SCHOOL CHILD; SCORING SYSTEM; SEPTIC SHOCK; SEPTICEMIA; SKIN INFECTION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE;

CHI-SQUARE DISTRIBUTION; CHINA; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

EID: 78649828816     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.1077     Document Type: Article

References (17)

1. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006; 55: 9-16.
2. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3. (Pubitemid 28483679)
3. Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns 2007; 33: 452-9. (Pubitemid 46702386)
4. Klein M, Rudich Z, Gurevich B, et al. Controlled-release oxycodone-induced seizures. Clin Ther 2005; 27: 1815-8.
5. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25: 246-55. (Pubitemid 38637782)
6. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference. J Burn Care Rehabil 2004; 25: 81-8. (Pubitemid 38116760)
7. Al-Mutairi N, Arun J, Osama NE, Amr Z, Mazen AS. Ibtesam el A, Nazeha el B. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 2004; 43: 847-51. (Pubitemid 39529949)
8. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003; 139: 39-43. (Pubitemid 36091572)
9. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32. (Pubitemid 36091570)
10. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 2003; 83: 430-2. (Pubitemid 37475783)
11. Bachot N, Roujeau JC. Intravenous immunoglobulins in the treatment of severe drug eruptions. Curr Opin Allergy Clin Immunol 2003; 3: 269-74.
12. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53. (Pubitemid 30637181)
13. Li LF, Ma C. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China. Clin Exp Dermatol 2006; 31: 642-7. (Pubitemid 44086789)
14. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol 2006; 6: 543-9.
15. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153: 241-53.
16. Petkov T, Pehlivanov G, Grozdev I, Kavaklieva S, Tsankov N. Toxic epidermal necrolysis as a dermatological manifestation of drug hypersensitivity syndrome. Eur J Dermatol 2007; 17: 422-7. (Pubitemid 47425910)
17. Paquet P, Pierard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 2005; 136: 205-16.